Goldman Sachs Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

In a report released today, Davinthra Thillainathan from Goldman Sachs maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$53.20.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Thillainathan is an analyst with an average return of 0.0% and a 57.89% success rate. Thillainathan covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Integral Diagnostics Ltd., and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh.

Currently, the analyst consensus on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is a Strong Buy with an average price target of A$48.11.

Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$1.45 billion and a net profit of A$399.08 million. In comparison, last year the company earned a revenue of A$1.28 billion and had a net profit of A$344.62 million